Cerevel Therapeutics Holdings, Inc. (CERE)

NASDAQ: CERE · IEX Real-Time Price · USD
28.15
-0.48 (-1.68%)
Jun 24, 2022 4:00 PM EDT - Market closed
-1.68%
Market Cap 4.17B
Revenue (ttm) n/a
Net Income (ttm) -242.65M
Shares Out 148.29M
EPS (ttm) -1.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,590,593
Open 28.91
Previous Close 28.63
Day's Range 27.68 - 29.41
52-Week Range 12.50 - 46.16
Beta n/a
Analysts Buy
Price Target 41.31 (+46.7%)
Earnings Date Aug 10, 2022

About CERE

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a sel... [Read more...]

Industry Biotechnology
Founded 2018
Employees 228
Stock Exchange NASDAQ
Ticker Symbol CERE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CERE stock is "Buy." The 12-month stock price forecast is 41.31, which is an increase of 46.75% from the latest price.

Price Target
$41.31
(46.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cerevel Therapeutics Announces Updates to its Board of Directors

CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that...

Cerevel Therapeutics to Present at the Jefferies Healthcare Conference

CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairp...

Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022

Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022

CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it ...

Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022

Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal epilepsy

Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chai...

Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results

Announced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety

Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it w...

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

In healthy volunteers, both the 7.5 mg and 25 mg twice-daily doses of darigabat demonstrated a clinically meaningful and statistically significant improvement in the Panic Symptoms List score after eigh...

3 Stocks Beating the S&P 500

Shareholders of Cerevel Therapeutics Holdings Inc ( CERE , Financial), Rexford Industrial Realty Inc. ( REXR , Financial), and Korn Ferry ( KFY , Financial) saw the value of their shares increase signif...

Other symbols: KFYREXR

Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program...

Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia

Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announc...

Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strat...

Companies will utilize cutting-edge brain organoids and advanced multi-modal “deep phenotyping” approach designed to enable the development of therapies with the potential to improve and reverse symptom...

Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates

Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022

Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it wi...

Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it w...

Cerevel Therapeutics Announces Departure of CFO Kathy Yi

Current Chief Accounting Officer Mark Bodenrader named as interim CFO

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...

New York, New York--(Newsfile Corp. - September 15, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breache...

Cerevel Therapeutics to Host Virtual R&D Event on October 7

Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of schizophr...

3 Biotech Stocks That Soared to New Heights Last Week

Find out what these industry favorites are doing to impress investors.

Other symbols: ADGIBCYC

Should Investors Follow Private Equity into Life Sciences?

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fun...

Other symbols: BBCBNTXCNCRIEIHPFE

Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fi...

New York, New York--(Newsfile Corp. - August 2, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breaches of...

Cerevel Therapeutics Announces Redemption of Public Warrants

CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE; CEREW) (the “Company”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience disease...